Knowledge Library

High-Quality and Cost-Effective Plasmid Platform

 In recent years, the demand for cell and gene therapy has increased substantially. With the success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality Plasmid DNA, key prominent market challenges are capacity availability, accelerated TAT and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Innovative Closed Process CAR-T Cell Therapy Platform: A Streamlined Approach for Manufacturing with Great Predictability

 Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Technologies recently announced the expansion of its service capabilities by offering a fully integrated CAR-T cell therapy platform to help accelerate the timeline for cell and gene therapy development, manufacturing, and release while providing greater predictability. This …Read More >

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW

AAV Suspension Platform Generation with significant Increase in Viral Vector Titer and Yield

The field of gene therapy has experienced significant growth in recent years. Adeno-associated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that …Read More >

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW

High-Quality and Cost-Effective Plasmid Platform

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

Resource Type: Webinar
Resource Topic: Advanced Testing Clinical & Commercial Manufacturing

VIEW

Lentiviral Vector Platform Generation: Increase titer and yield with greater predictability

The field of gene and cell therapies expand rapidly in the past several years. Lentiviral vectors have been in a great demand as gene carriers in this field, especially for ex vivo gene therapies. However, the large scale lentiviral vector production still remains significant challenges. WuXi Advanced Therapies have experience working with Lentivirus since 2015 …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW